Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000031193 | SCV001161595 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-06-18 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.000266 |
Invitae | RCV000048668 | SCV000076681 | benign | Hereditary breast ovarian cancer syndrome | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000130005 | SCV000184830 | likely benign | Hereditary cancer-predisposing syndrome | 2021-05-10 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001281714 | SCV000512312 | likely benign | not provided | 2020-10-20 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 30765603, 32546644, 28781887, 16267036, 8531968, 15004537, 16905680, 31131967) |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001281714 | SCV000605892 | likely benign | not provided | 2021-01-15 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000031193 | SCV000785870 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-12-20 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000130005 | SCV000903167 | likely benign | Hereditary cancer-predisposing syndrome | 2017-03-22 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000436368 | SCV000918792 | likely benign | not specified | 2018-11-01 | criteria provided, single submitter | clinical testing | Variant summary: BRCA1 c.4816A>G (p.Lys1606Glu) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 246164 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.4816A>G has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer (Fitzgerald_1996, Judkins_2005, Simard_2007). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Two independent publications spanning a decade report experimental evidence evaluating an impact on protein function, both of which demonstrate no functional impact of this variant on measures of yeast small colony phenotype assay (Coyne 2004) and a transcriptional activation assay coupled to a Bayesian hierarchical model that estimated the likelihood of pathogenicity (Woods, 2016). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (4 VUS, 2 likely benign/benign). Taken together, the emerging functional evidence surrounding this variant published in reputed recently published journals and recent classifications in data sharing databases (ClinVar) support the move towards a benign impact for this variant. However, additional evidence supporting presence in unaffected controls (due to its rarity), lack of co-seggregation with disease, and co-occurrences with other pathological variants in BRCA1 is awaited. Based on the evidence outlined above, the variant was classified as likely benign. |
Mendelics | RCV000031193 | SCV001140508 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000130005 | SCV002537786 | likely benign | Hereditary cancer-predisposing syndrome | 2021-02-01 | criteria provided, single submitter | curation | |
CHEO Genetics Diagnostic Laboratory, |
RCV000735492 | SCV003838737 | likely benign | Breast and/or ovarian cancer | 2023-06-05 | criteria provided, single submitter | clinical testing | |
Sharing Clinical Reports Project |
RCV000031193 | SCV000053793 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2012-05-01 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031193 | SCV000145189 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000031193 | SCV000591540 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion criteria provided | clinical testing | The BRCA1 p.Lys1606Glu variant was identified in at least 9 of 111320 proband chromosomes from individuals with breast cancer or who were referred for BRCA1 screening (Fitzgerald 1996, Judkins 2005); however, control chromosomes were not evaluated in these studies, thus the prevalence of this variant in the general population could not be determined. This variant was previously identified by our lab in an individual with breast cancer, and was also identified in dbSNP (ID: rs80356943) “With untested allele”, HGMD, UMD (1X as an unknown variant), and the BIC database (8X with unknown clinical importance). This residue is not conserved in mammals or lower organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein. However, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of unknown significance. | |
Foulkes Cancer Genetics LDI, |
RCV000735492 | SCV000863630 | uncertain significance | Breast and/or ovarian cancer | no assertion criteria provided | clinical testing |